SKB315 combination therapy for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called SKB315 combined with other treatments for advanced or spread stomach cancer. The drug targets specific proteins (Claudin 18.2) found on cancer cells, and may help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your stomach cancer must be advanced (can't be removed by surgery) or has spread to other parts of your body, confirmed by biopsy
- You have not received any previous chemotherapy or systemic treatment for this advanced cancer
- Your tumor has specific proteins (Claudin 18.2 and PD-L1) that the drug targets, shown by a tissue test
- You have at least one tumor that can be measured on imaging scans
- You are in good enough health to tolerate treatment (ECOG score 0 or 1)
- You are expected to live at least 3 months
- Your blood counts and organ function are adequate, and you cannot use certain growth-factor medications in the 2 weeks before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two experimental drugs (QLS31905 and QL2107) plus chemotherapy (oxaliplatin and capecitabine) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination helps shrink tumors and control the cancer better than standard care.
This Phase 1 study tests SKB315 to treat advanced solid tumors, with special focus on stomach/gastroesophageal junction cancer that has high CLDN18.2 in tumor tissue. It may help you if standard treatments have not worked or are not available, though early-phase studies mainly look at safety and the best way to dose.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests a new combination drug called LBL-024 in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the treatment can help shrink the tumor or slow the cancer's growth.
This trial tests a combination of chemotherapy drugs (LM-302, S-1, and paclitaxel) with or without an immune-boosting drug (cadonilimab) for gastric cancer that has spread to the abdominal lining. The goal is to shrink tumors and improve survival in patients whose cancer cells show a specific protein marker called Claudin 18.2.
Hear when a new Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.